Codexis, Inc. has demonstrated strong revenue growth driven by its proprietary CodeEvolver platform, achieving a 32.3% increase in top-line revenue in FY2022 and continuing growth into FY2025. Despite this progress, the company remains unprofitable with operating losses narrowing from -$68.1 million in FY2023 to -$41.7 million in FY2025, reflecting continued heavy investment in R&D and strategic initiatives. The firm manages liquidity through a $40 million Innovatus term loan facility with milestone-linked drawdowns and maintains a robust current ratio near 3.8 at year-end 2025. Customer concentration and reliance on third-party enzyme manufacturing introduce revenue volatility and operational risks that investors should monitor alongside execution of enzymatic manufacturing scale-ups and collaboration milestones.